Dr. Ehab A. ElGabry is a physician-executive with over 25 years of experience combining clinical practice, diagnostic medicine, and translational research in oncology and precision diagnostics. He holds board certification in pathology, with fellowship training in breast pathology and cytopathology at the University of Florida after completing residency training at the Cleveland Clinic Foundation.

Dr. ElGabry began his professional journey as a urologic oncology surgeon — a foundation that gave him first-hand insight into patient care and the critical need for precise diagnostics.

Over his career, he has held key leadership roles in diagnostic medicine:

• As Head of CDx Pathology and Senior Medical Director at Roche Tissue Diagnostics, he led the development of both digital and manual scoring algorithms and contributed to multiple FDA-approved companion diagnostics including PDL-1.
• He then served as Chief Medical Officer at Akoya Biosciences, where he guided translational research and clinical adoption strategies of spatial phenotyping technologies.
• Most recently, he led the U.S. Medical Affairs Diagnostics team at Daiichi Sankyo, Inc. before joining CellCarta.

In addition to his corporate and clinical leadership, Dr. El-Gabry has been active in advancing the scientific community: he served on the ASCO/CAP Task Force for Predictive Immuno‑Oncology Biomarkers and is a co-author of the ICI Predictive Biomarker Summit proceedings. He also served on the board of the Digital Pathology Association. He has authored more than 100 peer-reviewed publications and is a frequent speaker at national and international scientific workshops and conferences.

As CMO of CellCarta, Dr. El-Gabry brings his deep expertise in pathology, diagnostics, translational research, and biomarker-driven precision oncology to help steer CellCarta’s mission to support global biopharma partners in developing next-generation therapies with robust, clinically validated diagnostic and biomarker programs.